Reports in the British press of ulcer bleeding and other adverse effects associated with the nonsteroidal anti-inflammatory (piroxicam) contain "no new information" and refer to data from "uncontrolled studies and reports . . . involving relatively small numbers of patients," Pfizer declared. An article that cited 77 deaths in the U.K. associated with the use of Feldene was "sensationalized" and "misleading" in suggesting that the British govt. had contacted Pfizer regarding changes in the anti-arthritic agent's regulatory status, the company said.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.